“ Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts “ “ Partnership...
Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, entered a manufacturing partnership with WuXi Advanced Therapies, a global contract testing, development and manufacturing organization (CTDMO).
PHILADELPHIA, May 9, 2023 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). Interius has developed a process to manufacture INT-2104, an off the shelf lentivector product designed to create autologous chimeric antigen receptor (CAR) T cells directly in vivo in a patient's body for the treatment of B cell malignancies. Through this partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product.